<SEC-DOCUMENT>0001193125-14-131698.txt : 20140404
<SEC-HEADER>0001193125-14-131698.hdr.sgml : 20140404
<ACCEPTANCE-DATETIME>20140404160133
ACCESSION NUMBER:		0001193125-14-131698
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20140331
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140404
DATE AS OF CHANGE:		20140404

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GLYCOMIMETICS INC
		CENTRAL INDEX KEY:			0001253689
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36177
		FILM NUMBER:		14745931

	BUSINESS ADDRESS:	
		STREET 1:		401 PROFESSIONAL DRIVE, SUITE 250
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20879
		BUSINESS PHONE:		240-243-1201

	MAIL ADDRESS:	
		STREET 1:		401 PROFESSIONAL DRIVE, SUITE 250
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20879
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d706848d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, DC 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of The Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): March&nbsp;31, 2014 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>GlycoMimetics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-36177</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>06-1686563</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>401 Professional Drive, Suite 250 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Gaithersburg, MD 20879 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(240) 243-1201 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;2.02</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Results of Operations and Financial Condition. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;31, 2014, GlycoMimetics,
Inc. (the &#147;<B><I>Registrant</I></B>&#148; or the &#147;<B><I>Company</I></B>&#148;) issued a press release announcing its financial results for the quarter and year ended December&nbsp;31, 2014. A copy of this press release is furnished
herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with General Instruction B.2. of
Form 8-K, the information in this Item&nbsp;2.02, and Exhibit 99.1 hereto, shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;<B><I>Exchange Act</I></B>&#148;), or
otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant&#146;s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date
hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;5.02</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective as of March&nbsp;31, 2014, the Board of Directors (the &#147;<B><I>Board</I></B>&#148;) of the Company appointed Timothy Pearson to
serve as a director of the Company and as chairman of the Company&#146;s audit committee. Mr.&nbsp;Pearson will serve as a Class III director whose term will expire at the 2017 annual meeting of stockholders. There is no arrangement or understanding
between Mr.&nbsp;Pearson and any other person pursuant to which he was selected as a director of the Company, and there is no family relationship between Mr.&nbsp;Pearson and any of the Company&#146;s other directors or executive officers. The
Company is not aware of any transaction involving Mr.&nbsp;Pearson requiring disclosure under Item&nbsp;404(a) of Regulation S-K. Additional information about Mr.&nbsp;Pearson is set forth below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Timothy Pearson</I></B>, age 46, has served as a member of our Board since March 2014. Mr.&nbsp;Pearson&nbsp;served as Executive Vice
President and Chief Financial Officer of Catalyst Health Solutions, a pharmacy benefit management company, from August 2011 until its acquisition by SXC Health Solutions in July 2012. Prior to joining Catalyst Health Solutions, Mr.&nbsp;Pearson
served as Chief Financial Officer and Executive Vice President of MedImmune, the global biologics business for AstraZeneca PLC, and was a member of MedImmune&#146;s Executive Team. Mr.&nbsp;Pearson joined MedImmune in 1998 and prior to his promotion
to CFO in 2007 served as its Vice President of Finance and Treasurer. Mr.&nbsp;Pearson was also a founding officer and investment committee member of MedImmune Ventures, MedImmune&#146;s venture capital fund that invests in early-stage biotechnology
companies. Mr.&nbsp;Pearson, a Certified Public Accountant, holds dual Bachelor of Science degrees in Business Administration from the University of Delaware and Accounting from the University of Maryland, as well as a Master of Science degree in
Finance from Loyola University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the Company&#146;s compensation policy for non-employee directors, upon his
appointment as a director, Mr.&nbsp;Pearson was granted a nonqualified stock option to purchase 15,401 shares of the Company&#146;s common stock at an exercise price equal to $16.33, the closing price of the Company&#146;s common stock on the date
of grant, and which will vest and become exercisable on the last day of Mr.&nbsp;Pearson&#146;s initial term of office for Class III directors, which will be the date of the 2017 annual meeting of stockholders. Additionally, Mr.&nbsp;Pearson will be
entitled to receive a $30,000 annual retainer for his service as director and a $14,000 annual retainer for his service as chairman of the audit committee. At each annual stockholder meeting following which Mr.&nbsp;Pearson&#146;s term as a director
continues, Mr.&nbsp;Pearson will be entitled to receive a nonqualified stock option to purchase 7,700 shares of the Company&#146;s common stock, which will vest and become exercisable over a one year period following the date of grant.
Mr.&nbsp;Pearson has also entered into the Company&#146;s standard form of indemnification agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;7.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Regulation FD Disclosure. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;1, 2014, the Company issued a press release
announcing Mr.&nbsp;Pearson&#146;s appointment to the Board.&nbsp;A copy of this press release is furnished herewith as Exhibit&nbsp;99.2 to this Current Report. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01 Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(d) Exhibits </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:66.80pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit&nbsp;Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated March 31, 2014, &#147;GlycoMimetics Reports Fourth Quarter and Year-End 2013 Results.&#148;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated April 1, 2014, &#147;GlycoMimetics Appoints Tim Pearson to Board of Directors and as Audit Committee Chair.&#148;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"><B>GLYCOMIMETICS, INC.</B></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian M. Hahn</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: April&nbsp;4, 2014</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Brian M. Hahn</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:66.80pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit&nbsp;Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated March 31, 2014, &#147;GlycoMimetics Reports Fourth Quarter and Year-End 2013 Results.&#148;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated April 1, 2014, &#147;GlycoMimetics Appoints Tim Pearson to Board of Directors and as Audit Committee Chair.&#148;</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d706848dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g706848ex99_1logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">03/31/2014 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>GlycoMimetics
Reports Fourth Quarter and Year-End 2013 Results </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GAITHERSBURG, Md. &#151; (BUSINESS WIRE) &#151;&nbsp;GlycoMimetics, Inc.&nbsp;(NASDAQ: GLYC) today
reported financial results for the fourth quarter and year ended&nbsp;December 31, 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In its initial public offering completed in&nbsp;January
2014,&nbsp;GlycoMimetics&nbsp;raised net proceeds of&nbsp;$57.4 million, after underwriting discounts and offering expenses, from the sale of 8,050,000 shares of its common stock at a price of&nbsp;$8.00&nbsp;per share, including the full exercise
of the underwriters&#146; option to purchase additional shares. Giving effect to that transaction as if it had occurred on&nbsp;December 31, 2013, the Company&#146;s cash and cash equivalents balance as of that date would have been $59.7 million.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the quarter ended&nbsp;December 31, 2013,&nbsp;GlycoMimetics&nbsp;reported total revenues of&nbsp;$77,000, compared to&nbsp;$3.8 million&nbsp;for the
quarter ended&nbsp;December 31, 2012. For the year ended&nbsp;December 31, 2013, total revenues were&nbsp;$4.0 million compared to&nbsp;$15.3 million&nbsp;in 2012. Under the terms of its collaboration with Pfizer, the Company received an upfront
payment of&nbsp;$22.5 million&nbsp;from Pfizer in 2011 that was recognized as revenue through&nbsp;March 31, 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s research and
development expenses increased to&nbsp;$3.0 million&nbsp;for the quarter ended&nbsp;December 31, 2013&nbsp;as compared to&nbsp;$2.7 million&nbsp;for the fourth quarter of 2012. This increase reflected the Company&#146;s completion and data analysis
of its Phase 2 trial evaluating its drug candidate GMI-1070 for the treatment of vaso-occlusive crisis of sickle cell disease (VOC), as well as advanced pre-clinical testing and manufacturing of its clinical-stage drug candidate GMI-1271 for the
treatment of acute myeloid leukemia (AML) and other cancers. Research and development expenses similarly increased to&nbsp;$11.7 million&nbsp;for the year ended&nbsp;December 31, 2013&nbsp;from&nbsp;$9.4 million&nbsp;in the prior year, with the
increase largely attributable to increased manufacturing expenses for GMI-1271. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s general and administrative expenses increased
to&nbsp;$0.9 million&nbsp;for the quarter ended&nbsp;December 31, 2013&nbsp;as compared to&nbsp;$0.5 million&nbsp;for the fourth quarter of 2012. General and administrative expenses for the year ended December 31, 2013&nbsp;increased to&nbsp;$2.9
million&nbsp;as compared to&nbsp;$2.2 million&nbsp;in the prior year. Each of these increases was primarily due to costs associated with the Company&#146;s IPO and other financing efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;On the heels of being the first biotechnology company to complete an IPO in 2014, we look forward to a productive year ahead. Notably, we anticipate
beginning clinical studies with GMI-1271, our pipeline candidate that will initially be investigated in acute myeloid leukemia, and we expect our partner Pfizer to move GMI-1070 into Phase 3 study in patients experiencing vaso-occlusive crisis of
sickle cell disease, which would result in a milestone payment to us under our agreement with Pfizer,&#148; said&nbsp;Rachel King, GlycoMimetics&#146; Chief Executive Officer. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About&nbsp;GlycoMimetics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GlycoMimetics&nbsp;is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical
needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics&nbsp;are molecules that mimic the structure of carbohydrates involved in important biological processes. Using its expertise in carbohydrate chemistry and
knowledge of carbohydrate biology,&nbsp;GlycoMimetics&nbsp;is developing a pipeline of glycomimetic drug candidates that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains
forward-looking statements regarding GlycoMimetics&#146; planned activities with respect to the clinical development of GMI-1070 and GMI-1271, anticipated milestone payments from Pfizer and other matters. Actual results may differ materially from
those in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing&nbsp;GlycoMimetics, please see the risk factors described in the Company&#146;s Annual Report on Form
10-K for the year ended&nbsp;December 31, 2013&nbsp;to filed with the&nbsp;U.S. Securities and Exchange Commission&nbsp;and other filings&nbsp;GlycoMimetics&nbsp;makes with the&nbsp;SEC&nbsp;from time to time, including those factors discussed under
the caption &#147;Risk Factors&#148; in such filings. Forward-looking statements speak only as of the date of this release, and&nbsp;GlycoMimetics&nbsp;undertakes no obligation to update or revise these statements, except as may be required by law.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">GlycoMimetics, Inc </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(A
Development Stage Enterprise) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Condensed Consolidated Statements of Operations </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(In thousands except per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Three&nbsp;months&nbsp;ended&nbsp;December&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Year ended&nbsp;December 31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">(Unaudited)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2012</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2012</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost and Expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,701</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total costs and expenses</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,581</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) from operations</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,862</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,588</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,662</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) and comprehensive income (loss)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,867</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,605</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share - basic</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.80</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8.87</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share - diluted</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.80</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8.87</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares - basic</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,380,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">929,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,196,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">929,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares - diluted</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,380,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,016,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,196,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,016,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">GlycoMimetics, Inc </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(A Development Stage Enterprise) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Balance Sheet Data </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(In thousands)
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">December&nbsp;31,<BR>2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">December&nbsp;31,<BR>2012</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GlycoMimetics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brian Hahn,
240-243-1207 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>bhahn@glycomimetics.com</U> </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d706848dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g706848ex99_2logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">04/01/2014 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>GlycoMimetics
Appoints Tim Pearson to Board of Directors and as Audit Committee Chair </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>- Pearson, former CFO of&nbsp;MedImmune&nbsp;and Catalyst Health Solutions,
Brings Broad Biopharmaceutical and Public Company Financial Experience to GlycoMimetics Board - </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GAITHERSBURG, Md. &#151; (BUSINESS WIRE)
&#151;&nbsp;GlycoMimetics, Inc. (NASDAQ: GLYC) announced today the addition of&nbsp;Timothy Pearson&nbsp;to its Board of Directors.&nbsp;Mr. Pearson most recently held the position of Chief Financial Officer, Executive Vice President and Treasurer
at&nbsp;Catalyst Health Solutions, a publicly held pharmacy benefit manager with over $5 billion in revenues. Mr.&nbsp;Pearson led the company&#146;s financial activities, including performance management, investor relations, SEC compliance, capital
strategy and planning, until&nbsp;SXC Health Solutions&nbsp;(now Catamaran Corporation) acquired Catalyst in 2012. Mr.&nbsp;Pearson had previously served as Chief Financial Officer and Executive Vice President of&nbsp;MedImmune, the global biologics
business for AstraZeneca PLC, where he had functional responsibility for finance, information technology, strategic planning and governance, and was a member of MedImmune&#146;s Executive Team. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Having completed our initial public offering in early 2014, it&#146;s ideal for us to now be adding an experienced public company CFO to our Board
roster,&#148; said&nbsp;<U>Rachel King</U>, CEO of&nbsp;GlycoMimetics. &#147;The addition of Tim to our Board of Directors comes at the perfect time for our company given his financial experience at&nbsp;MedImmune&nbsp;and Catalyst Health
Solutions.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Pearson&nbsp;was appointed CFO at Catalyst Health Solutions in July 2011. Before that, he spent 13 years at MedImmune in roles
of increasing responsibility. Prior to his promotion to CFO of MedImmune in 2007, he was Vice President of Finance and Treasurer with responsibility for treasury, corporate finance, tax, risk management, Sarbanes-Oxley compliance, internal audit and
equity plan administration. During his tenure at MedImmune, Mr. Pearson was a key leader in a number of MedImmune&#146;s financing and M&amp;A transactions, including its $500 million acquisition of U.S. Bioscience and its $1.6 billion acquisition
of Aviron, as well as related post acquisition integration efforts. Mr. Pearson was a founding officer and investment committee member of MedImmune Ventures, MedImmune&#146;s venture capital fund that invests in early-stage biotechnology companies.
Prior to MedImmune, Mr. Pearson held various financial roles of increasing responsibility at Integrated Health Services, CIGNA Insurance and First National Bank of Maryland. Mr. Pearson, a Certified Public Accountant, holds dual Bachelor of Science
degrees in Business Administration from the University of Delaware and Accounting from the University of Maryland University College, as well as a Master of Science degree in Finance from Loyola University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Following GlycoMimetics&#146; IPO and as the company prepares to bring its lead oncology program into the clinic, it&#146;s a great opportunity for me
to join the Board of Directors and to help the company push forward in achieving its objectives,&#148; said Mr. Pearson. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About GlycoMimetics, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GlycoMimetics is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs
resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics&nbsp;are molecules that mimic the structure of carbohydrates involved in important biological processes. Using its expertise in carbohydrate chemistry and
knowledge of carbohydrate biology, GlycoMimetics is developing a pipeline of glycomimetic drug candidates that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GlycoMimetics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brian Hahn, 240-243-1207 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>bhahn@glycomimetics.com</U> </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g706848ex99_1logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g706848ex99_1logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`,P#R`P$1``(1`0,1`?_$`+D``0`"`@,!`0``````
M```````'"`8*`P4)!`(!`0`!!`,!`0`````````````!`@8'"`,$"04*$```
M!@(!`P,#``8$#P$````!`@,$!08'"``1$@DA$Q0Q(A5!(S,T%A=1,G>W<4)2
M8G)#8[,D-;8W.#EY"A$``0(%`P,"`P0%!PP#`````0(#`!$$!08A$@<Q01,B
M"%$R%&%Q@16Q0B,S=9%2<K,T%C>AT6*BLD-38R1TM#88.`G_V@`,`P$``A$#
M$0`_`-_CB$5:VQW4UBT?QK(96V=R[5<7U9F@LHR1EGR:MCL;A(AC!'56LMA5
MFK`_4,7M`K=$Y2"("H8A?NXB0DJ,A&LMG/RJ^1+>2)2L^IZ=2\:.FZLH0:EM
M3M*BHWRKFYVU7`\:WQUBT(^6F3U.4,9,7+MO'NVZ+?N.H\*4!*';H;?<+I4?
M26QAZHJMI5L:0IQ<AU.U`)D.YE(1U+G=+/8:/\POM534E$%!/D>=0TWN5H$[
MW%)3N/83F>PBQ.O?G9R?KA.U+#/F#Q0QQ&:U"T8XLW;PR)[]JKF=JHJ#1K-+
M62O"_8UET][!45*F<YDSB(*-6Q0'ITS,**5`A0,B#H01U!!U!'<&1$=_QI6@
M.LJ"FU`$$:@@]"DB84#V(F".AC9:I%ZI>2ZM"WC'EKKUWIUB9)2,%:*K+L9V
M"EF2Q0,FX8R<:NX:.""`]![3")3=0$`$!#DQQ2EUC*^(0XA#B$.(0XA#B$.(
M0XA#B$.(0XA#B$.(0XA#B$.(0XA#B$.(0XA#B$.(0XA#B$.(0XA&O9Y)O*EL
MY0MC9;0#07#%=L.Q++%[;*N1,[Y@G8^O8:P1C=_W%6O,L1Z`IRA8<`**@K=R
M'>H4G88PAP`I2@E()43(`"9).@``U)BL!M*"Z\H);$R23(`#4DDZ`#N3TCP"
M88XH3+(JV>\Q7F2\C&WKI8CPNR.>F#X==L52J)P5(A@#!<D?XEQ+$+#VLI.5
M1!@4I0]M/ITYM-Q7[5\QS=+5WRDJL^-+D1O$ZEU/7T-GY`?YR_OD(T.Y]]_?
M&O%JG\;P,-Y%FC<TD-J(HV%]/VKP_>D==C9EH028S"PS=AN5C=7*\V.9N]Q>
MI%0<66S.0>O$FA.X$HR(:`4L;7X-J4W:@R9I)((D`"E#IST0P/C3#.-K;^78
MI1H9)`\CRO6^Z?YSCBIDS^`T$>-7+7.7)O-MY-WS^Y.U#:5'Q4R#XZ9A,R0E
MIE,DB4Y;B-Q[ZQV-9ML[48.Q4V/0K5EQC=3%_F!A+)$$WN>&K^B'3O)-5"0*
MJG"R2H!T))Q@MWJ)ON*/7F/>4?;K@G)0<N"6Q;<G4)BJ82`%GMYF_E<'Q,MW
MP,9@X&]Y_+'"*F;2Z\;W@Z"`:*J626T]_IGC-;1'9,]A[@Q^-?*[E[6J\A:?
M$WF9[@:]V.1!U/>-S8JQN;9KGE]T4BBCEK@'*<LHJE!3#H!5(SBWWM/T3*%3
M14$>><O)7"F=\7U!5?:<O6<J(15LS4RH=MW4MJ/\U7?O'M-PG[GN)N>:-(Q>
MM%/D:4`NT%00BI;/?:#(/)'7<C61'IC:5\5OD76\C>$;E>+%A^:P;E'$.1IC
M#V7L>RL@C+-(?(%<(4)A*%DDBE,XC2JB(%!3JHF/VF,8?7F)8S^M.TR[1Z>\
M13#B$.(0XA#B$.(0XA#B$.(0XA#B$.(0XA#B$.(0XA#B$.(0XA#B$.(0XA#B
M$.(0XA&F?O40BOEY\D:2A"*)*>+2I%424*4Z:A0R#4A[5$S`)%""(>H"`@/+
MJP3_`-XLW\4I?ZY$6-RM,<6Y"02#^1U_30_V9SN(J$L8QC]QA$1[$@ZC_0"9
M0``_H``^@?HY[E+)*IGK'Y5FP$ID-!,_I,<7*8KAQ",NQR4JF4\-IJ%*HF.;
M,/J=BA2G("B>1:X9-4"F`2@JF/J4P?<7]`\P_P`^_P"#E_!Z?13_`-=$;'>T
M33W(XDH:*_,I?@6US'W'N.ACV$__`#OK)-Z[Y,W#A4B*"/D2S:LNNJ<")I))
MJE.JJJH<0*0A"%$3"(]``.O/&IO]VG[A'Z6*G]\K[XL15MK][?(#:;U*Z#AA
MS`^J="M]@Q_#[/9RK,QDB>SE::I(&B+2^Q1BV)DJ^W0HD%,MEF9)62?I`^62
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M"T-$YJ.:.P`6KR99-OD*PS5<INI%'0)%,7U#T]>(D(4K4"+.1N4\:S&/4<M1
M5^J$CBYQ!&LZ.0F=ABEZ:I72(F<'FRV--T:*&+(B43&6]WL``'J/$1(SEWBK
MV$O)+H?L?D);%&$-J,.9'R(0')VM3KUN8KRTNDS[_EKU]%4R(6!!L"8B<[,5
MP*`=1]/7B)*5`3(TB!?(EN[D#5:XX7@<?EKZZ-F/*S-V;S$4,DNK`QS^';)M
M6*I7C7\<Y=)N5^U40/ZE^GH/-JO;QPEC_*=GO-?D!J$KI@ANF+:]@#JTN$J4
M-JMX20F:=.O76-!?>-[H<MX$R+&[5B::-;==Y7JQ+S?D466W&4A*#N3L*@IR
M2I'4#X2,A[V[C2>OVO%.R+B]U".;?DR1A4Z8>89#*1IH=U%_FI*4.S3<MO?(
M@T50('W]`,N4?7EO<%<.TV?\A5F.Y0E]-HMC;GU`;5L7Y$K\:$;B#(E04>G1
M)B\_=-[D*KB/B&V9GA2Z9R^7MYGZ3RI\B"RIKS.N!.Y.Z22VD:R!6#$495V>
MS7.:R:H99Q[D7'E!L62;)66U\4L@,F#277=$23>1$,C('6231^8505TB'%?V
MC%`@]0'EUXKQCA5#R9E>)Y#;KC7VZVTSRJ4,[EJ;"9E+CA1(D[9;5$;=P.X1
M8.<\X\F7;A'`<^Q"[6FUWF]5;":[S[&TNJ4`%MM!S<`D*"BXA)\A24A)F#%V
M[3MGKUCM]/UW(67Z17K33&D>>VQ+N1%!RQ<O4VWMD0:*$^0X%PJX**:9`.IV
MF#J'UYA.U\3<@Y"Q3W''[16U%JK5K\#B432I*29S4-!(`S)D)B-G+WS_`,18
MA655DRW(;927^VMH-4TIS:I"E!.B4$;E3*@4I2"J1&D=6^W7U6CJ7&9`=9NH
MY*M,O5XV->DDP5<.7[4"&=-2QJ1#R15FQ%"F4`R0=A3`(^@ASLL<*\IU%Y=L
M#5DKC=&4!:T[)!*3\JMY.R1D0)*U(/PCIU/N6X*H\<8RM_)K8++4.*;;4')K
M4M,MR?$`704@@JFC0$$]1$R0&5L;VBA)Y1@KK79''JC!:3_BY*2;EA$F383%
M=+.'JAR)-OBG()5"G[3$,'00`>6=7XIDELOQQ>NHJAO(`X$?3E!\A4?E`2-3
MNZ@B8(U$9%M6>X9?,4&<6NYT;N(EI3AJPXD,I0GYBI9("=I!"@J1!$B)Q$]`
MW(UCRC:DJ31<RTR?M#E4Z+&(;R`HKR:J?7N3BS.DT$I$_0HB`(F.(A].O+LO
M_#G)N+VHWN^V:L8M:1-3A1,(![KVDE`_I`186*>XSA/-[ZG&<8R*W55\6K:V
MT%E*G5?!HK"0X?L03/M%-KSO6ZA-\J]@^,R)26^)%*Z[A[$J]CQ47C<G'9S#
M>/A'4P54ITE#S`,BBD4@]>_MZ]3>F8['P6U6\$5&;U-NK59:*A+C02N071;F
MRMQ+<I$!OR'<3VG+2-;<H]U#]K]U5+QA1WFV-X`:13+Y6W-2+D4/I0RIV<P?
M,&!M`/7;.9B7-&<P9-N&-<K6S.^4\<V]M5<AST>UL=9>QR,9`PT>U;N7#:7=
MMQ29MD4/>!1(%!]TB)@[Q$>6ESCA^,V?)+5:<$M=QHW:NWM+4R\E96ZXM12"
MVDS4HF4E$>DJ!VZ1D7VO\C9ED>&WZ_\`*%\M%?36^[/-IJ&%MAMAI"$J4'5I
MVH2D;@I`5ZP@C<9Q+]6W:U3NEL0I%:SA19.R.W/PV+(DH"*<@[%3VBMH]ZY(
MBR>+J']"E34,)OT=>6?=.%.5+-:57NY6.N:MJ$[E*V3*$RGN6D$J2`.I($N\
M9$L?N8X)R._)QJSY-;';NXO8A'DVAQ9,@EM:@$+43T"5$GM&4Y1VDU^PO/1U
M8R?E2J5"?E$DG#6*DWW1V5JNH*2+MTDB146314Y1`JBO80>@^OISY>,<79_F
M=`Y=,9M555V]HD*6A/IW`3*4DRW*`ZA,S'W,WYSXEXXNS-BS6^T-!=WDA26G
M%^L)49)6L)!V(,C)2Y#0ZZ1-\7*1LW',9B'?M)2*DVJ+Z.D6#A)TR?,W*956
M[IJY1,=)=!9,P&*8HB!@'J'+(JJ6IHJA='6-K:JFE%*T*!2I*@9%*@=00="#
MTC)M#745SHVKC;G6WZ!]M*VW&U!2%H4)I4E0F%)(U!!D1&"YFM<I0\/Y6O$&
M#8TW3,;7FUPY7J1EV9I2NUB4EX\':)3IF5;"[9D]PH&*)B]0ZAS@CN#4RCSG
MUZ\HF"F>G.L6:-R\Z8?Q!E'-&"VN79&`D)5&NA,-$7Q8V7?5&NN7#N3?M&[]
MP@B"*'OJBHH```]>(J*3N(2#*+D:U[CZR[?PL].:XYBI^4FU4?I1EK90+XQ)
MRKOW"8JMFUBK[Y)I-0QW:11.B+A`A52@(E$>@\124E/6(7RQY4/'S@_)$IB7
M*&U&+:O?:^\2C[5#+RZKU.FO5C@0C6YR<:V>1=57`Q@[B/ED#$_Q@#B)VJE/
MM%Z*[8X"WP,/::K-1EBK=@CFDO!ST*];R43+Q;Y$CAG(1S]HHJV=M'2!P,10
MAA*8H]0'B*8[GB$::.\__M\\D'_RUJ7]X%3Y=6"?^\6?^*4O]<B+&Y6_PLR'
M^!5__C.13]3^L'^@G_NR\]RE_-'Y5T=/Q/Z3''RF*H<0C+\;_P#=;#7]M.(O
M[Q*YS#_/O^#E_P#^Q/\`MHC8_P!HO_V0Q/\`B8_JUQZG^":N2%QPSY;ZC$NS
M1\K:=WMEJY&/RG%,S*0G(A[&,W95`]4S-G+HIP,'T[>O/&IO]VG[A'Z6*C1\
MG[8O+X4LMTUYIA2M57"D?2]C-04I["V<\/2HIQULJMIK]BF3,K8O`K*ED7M7
MOS!TA+M)(A!;N_EG`IQ,4W*XXW`=V[L8K!G#:/RE8+V7UUUY1SKI?F;(^>,R
MQ,2;"]!P_=6M^I>"&[]:3O.6+@]6R&_1K,%6*PW!NF[=MR)OI%P0B(&$!*")
M`003KTB&)#`-BSQB/S&.<>HG-FK!/DCL>R&#7:!2@Z0RAARL5.S1[1H82G5`
M+%%H/(TQ"B`J%=@41Z<DQ,Y%,^DHF#7O-R_E-VMA=K*&U0F\2:/ZO'-0XI1N
MJ>-7WNS'4W(W"/59O`,4TOAJ$9K1)C%#O;/'I3%-W=!Y'Z(A0V)EW/Z(L/X3
MZ=@VWZ1-+XXA*G;-@,D7');C=&:LT=&S&1'N?!N5@97BKY,/*INI9O\`@6Y4
MV;"/<B5!&**C[28)F]40[,*^SM%--N*7HW4,1X,Q!A"TQ3?Q_P!L\FL=7-TH
MNIVV6DL15"QNF4M*-\9J*KN5J]5<62^6F\>G+1L:/X0CI3VE`*)C%Y$5)*IS
M(]6W2+E^:"@:\570"QW!""J5*REC%>FO-.9^BQD1!WR!S8$]#M\=0F(G$*@W
MDB+S2YRMEF3`?:<,#*`H0R8#R8H1,JB'LKXZL&W.Y:6,+ZT3&S4G3IBO9FI0
M)\>'R=+50CM=T0B9C(MU6%OG$``I>@"5,`^G-[>,\F<XI]OE%EB"4/W#)&Y_
M%;*5I#B/M"FVW!]A,>4W-^"-<_>[FYX&ZE+E%:<.>2C6?CJ5-+4TY]A2\^P>
MT]H!BN&!8RY[F6;&^$+S'.3U[5K#N2V,BU5.J8K^;1-(Q5<(JF<IBHN$%3,4
M2$[0$?A#T'IS+V>55FX;MERS>QN)%PRF\4:D$2]+9V+>E\01Y5$_\P1KGQ70
MY'[D;W:.*\E86;+@N.7%"PJ9WNCRM4Z5`SVJ!+"`-#^P/;2.%Q8%I71K6ROO
M%#'?T#;R1J;DBA@.=%)!^B[9ICZB)>U!<2@`]/0O*F[>BDYPR2X,B5/7XBA]
M,NY*2E1_E$XFJNJJSVQX7:'E;JFT\@O4ROL3HX@?@%$?A%YZ%A['F7_*3LRC
MD:K0]OBJI3(R4CX>=9IR$:,D^;5R,!XNR7`[==5LV<G]KO*/8<0.7H8H#S!M
M^S#(<1]KN-.8Y5/4=555JT+<:44+V)+R]H4-0"0)R(F-#H3&TF+\;8;R)[Z<
MT1F5#37&AH;8AU#+Z`XWY%IIF@LH5-*BE*E;=P.U1"A(@&(YT8ULPG=,L;QL
M+30X6>C*);I>GTZ+EFB;YE78AZ]M(**1B;@#E;2":3!$B:Y0!1,I/M$.H\N3
MG+DG-;-BF#OVNO>IZFOI&ZBH6VHI4\XE+$@LB4T$J45).A)U$61[6N$>+\DS
MWDZFOUJIJNBM=>]24C3J0M%.TMVK!+05/:X$MH2E8]20G0B<5$7<6MKXX)F&
M@W+IO3R[3.8BVJ`HY%HS@DC#^.3D3(&]Q.'4?`)G!2]"G,`=0[NWF6D-VIWW
M',UE<E*KO_=<.,"0W*=/SE$]"X$Z(GJ!/M.,"MNW^D]G51;K4M:<>_OLINI)
M*]B&MDVDKV>H-%R94!H5!,_5*)<N^$+C=:SBB(;9(\?V/ET92">8ZLF.Y$U8
MNCEZ@B@NU;KR\:V.[]QR8H"J#P2_\0(AU`_+3LF;6>RW.ZUCMMS^X(4TZFK9
MJT>:G2DDA1#:U;9#]7QS]':47]DO&V09-9+';J:\\3VEX.LJH*BWO?3UJEA(
M*4K=;;*YDR*O.4_M.X5%@+1C&K)^4?#L!9JK67S][A0EJN9$8Y`T=-9$85>Q
M.W5H.D9(A5G_`.6CR+)KF*"@"0IO00Y8%LR>Z*]K]XK[955+=.B]%BGFL[VZ
M13S*4L`ST3XUE)2#+4CI&5;U@M@3[Y\?M5]M]"]6.8TBJK)-I+;UQ12U2EU4
MB!N7Y6TK2L@*FE)T($4A8/9]MH=D5%JK*M:5(;L':Y-=0_<5=*J&B8L3E=&)
MZ_!,J`B(&_5F5(F`^O;S-E0S0.\[VY;H:5>F\*W427.A?\B_EG^M+X:A)5+O
M&MM$[<VO:S>*=I3Z,8>Y(V7%36[<*?Z9H@';KM*AW])6$!7:/7$F._%R-(Q(
MH^+A))D=]75*A(MI=LA8Y&;."!VI;`YBG(3*HK.@`5RR(@AW^A^GIS4LY%[H
M?SN[)8_.U/!#HJ$*;464-B>[Q!8\8DGY2S-4ND;^M8C[&&\8Q\U)QEM@N4YI
M5I>2BI<>(3M%0II0>.Y7[P5$F]VBNT5&WGQO5J=GS(><:=9L&9359TR(1RU@
M3)KE@O-QD$FU;HMWM0[UF[I%\JQ:IG2*R62?-A-WAW%4`!RWP=D=TO.`V_"+
MQ37RU)76.&@NE$E0;6Z5$E-1($%(4HA1<2II<MNA22-??=+A^/8URI>.4+!6
M8O?UM6YH72QW);9>:9"$)"Z29"MY0A!2&5HJ&Y[AN"P#Z^8#R]CBSX8PC/1K
M>$QM'9`J[!.DT=V]8Q_M"Q:)D6@8%$XMRR!6!"_JP2+W&3$INWUYJ'GV(Y';
M,SO=#4J?N51;ZI1J:E*5+GN42'72)[-W?<9`S$X]"^).1,+OG&F+W6A12V2B
MN]`@45$I:&Y>-`"F&`=OD\8'I"1,ID9:QWVS/_C?L%_8CE?_`*#GN8ZC-`ZB
M-8W0/'M(O^QO@Y7NE7A;0:B^,/,%SJ19M@VDD(2TIVZ#B4)UFW=IJH$DFC)\
MH"*O;WHG$#D$#``A'>.11(2?Z7^>+S[V5NS8O\AM1OFM<82OYTS/XW=XZZK_
M``VQ1:.;M;\51]$G,++2*+0B82TY7K/9%2,%50.HD57VRCVCTY,0D^F1Z3$6
M0\3]5U*D/&[AP^-XW'L_4)_'!7N>WL^UAI.3E\HNXX5,S*9K5F4U72UP"Q?-
M"8++_K4^T0.`)@'$'-V_7\(L'IM*:18PU^@8[5*\U"*UW>9'M=>H:ZMUE5*:
MO<I&PN$Y:IXW?WF1[%X8)_W48YA$G-'%$#$9$[/3B*5;B?5UB\W$4QJ)^6;"
MNQNN6]^8=ZEM<;GL=IQGG5R'UPS*?!DD97-6(XN/DV<P[OD97E$C).AC)&/;
MG3,<#MEDQ.F<`-TYW+=7U-JN#%THB$UE,\AULD3`6A04DD=P"!IWCIW6TT&0
M6>JL-T256^LIW&'4@RW-NH*%@$:@E).HU$4#I@U7+=$>Y8UXR%%[%XMB@$UE
M>U2./%9DQ0!`Z*,LY844$;)5EV/3M7D622L:8WJ7IST?XM]W..Y%XK1R&A-L
MO2I)%0G^RN'035/5DD_'T_"/%;GS_P#.S,<.+^1<...7O&TA2S1KE]<RD3)"
M)"50``3Z?7\0(^%NNW=H)NF;A!VU5#JDY;*E60/_`$@!R"/:<HAT$INABC]0
M#FX-/44]6PBJI'$.TK@FE:"%)4#T(4)@QYNUE'66ZK<M]Q9=IZ]I12MIQ)0X
MA0,B%)4`00=(Y$RKN9"/AHYC)S4]+K$;0M;@8]S,V.:<J&`B;:)AF)%7CM4Y
MC``"!0('Z3!SXN395CN'6Q=XR>L9H[>@3W.*`*OL0GJI1[`#6+IP;C[-.2[X
MWCN"VZIN5V<5+:T@E*?])Q<MJ$CN5'2/MLV3L6ZO9#HS/**UCR_LDUL=>L>-
M]$=:A;W[-4O:8=^TF:V&<K/#B[A,40"<L@@HZCB'&243(9,XE]>>>/-?NE7F
M]LJ</PVE\.-U"=CK[X_;/)!!DA'1M)(ZGU1[)>V#V$-<77NBY'Y(KQ59I1K\
MC%-3*_Z:G64D3<<E-Y8!Z)]`,]8V%_!#JILUK?@G/UPVIH\+C#(NS^QMSV$2
MQM&2QI=]2(RY@59*"GE1*`-I1J;T,B(F.F'H<>[FG0```'01Z0.JWK*HO!LS
MXVM0]L+4RR'E'&ZT=E)BS2C$LKXXL,UC;)*T2B(BG$R%MJ3N.D9:.3Z_8FZ%
M8$P]"]H>G)BD*4GITC*-7=!]6=/%9V5PCC-I&7.U$(E;,F660D+ED^SMTCF4
M0:35ZL:[^><L$#&ZD;E5(@`^O9U]>(*4I76,G'#<!KW3]E[UKOC=O*Y4R]+W
M#,,K7E)($&^0,Q2%?(PCSOG3]3XL<VDG#!JDL(=$R)`8>G7B(G.4^D0]XR]2
MG&G&IE/QU8XN$C,JW*;M.9,Y?P\5#\0OF#*4PO9[BE'&;III'CXE=RFP0$O4
MHIM0,'];D#I$K5N5/M&-9L\3FEN=,D3^6)VCVFD76Z=ILB/\0Y`M6+6F2UB]
MA/EW^,J+]@PLL@=`@)'<K)_(42^TQS<F)"U`2BSD1J1K1!8"-JW&82QZVU]5
MA5:^YQ3_``\S4JCV-74%9Q\YFH0QWC]PY'WCNU#F=&7_`%GN=_0W$1N5NW3]
M45>PQXE-(\'9$KN3ZWCZQVFRT=8[C&Z.3K]:\CP&,'!NXI7./Z_:9%_%UQT@
MB;VT54TS*HDZ`0Q1`!XB2M1$HNE7,(8QJF2[CE^"J[-ED6^M$&%ILH&54>R;
M-L#($6Q_<.8B:10CD?0H!U]L.77<<WR:ZXU1XA752UX[0+*F&=`E"CNF=.I]
M:NOQ,8^L_&.$V'-+AR':Z%MO+[JV$5-1,E;B1XY)U,@/V3>@E\HCY\?8$Q)B
MNT7>Y4*EQ5<L>1'HO[=),DS%5E7!G;M^83@8QB))F>/E5!*0`*)C?X.<N09[
MEN4VRBLU^K7:BW6Y&RG0HZ-C:E/XG:E(F=9".#$.)N/L#OESR3$[8Q1WF\.>
M2K<0#-U16MP]=`"MQ:B!(3,1L;2K6HT.>`'&<4$.>]ADOX`*NBMRW4`*7\V0
M@*_8N8I``0#[1#TZ<N,<T\E"K%?^9N_6"A^CW23/Z?\`X9TZ=_C%G?\`QJX8
M^A-L%E8%!^9_F&P*5M%7MV^4:Z';Z9=):1*L!A7&E7R7;,OP=8:,<AWA@WC+
M/8DS*BZE&346ID4%BF.*8%(+)+Z``_8'+6K\UR6Z8U28A75*W,>H7"MEDRVH
M4=TR._ZROY8ONT\:X78\TK^0K91-M9=<V@W4U`)W.(3LD")R_P!VCH/U1'!0
M<&8NQC+WZ<I%4904IDZ5/-79TV,J)IN14.]4.X7`YS`43*2"P]"]`ZG'E=^S
MG*,GI*"AO=6M^EMC0;IDF7[-`"0`)?8A(U^$<.)\68+@]?=KIC%`W2UU[>+M
M8I),WEE3BB3,Z>IU9D.ZC'4U+6["=)HEDQG`X^@DJ);WKZ1LE:=M_G1LL[D>
MGRU7*+H5`$5.T.G3H)1`!#H(<[=VY(S6]WVFR6ON#YOM&A*&7DG:MM*/E"2F
M73_+WCH8_P`,\9XSBU;A5JM-,,6N#BUU%.L;VW5+`"BH*GV`E*4I"4HARA^/
M74G'%Q:WJMXGBOSL>[^=%?E5G$O'Q+PINY)Q'1SXZK5NH@/JF/:/8/J'KR\+
M][@^6<CLZK'<;L[]`XC:OQ@-K<3W"UIDH@]]=8QYBWM(X$P_(49/:+$R;FTY
MO;\JE.MMK!FE2&US2"D_*2#+M$[R&"L62N6(W-[^J,G&3HB%5KT?:#&5^6WB
M%FSUHHS*4#@D)#-Y!8OTZ]#CRQ:?.LII<4<PEBK6G&77@ZMG3:7`I*@KXSFA
M)_",HUG%F"U^>L\FU5`VO-J>F+"*F9W!HI6C;*<OE=6.G11CJJ=K9A*ATNVX
M[KF/H)O2;S)OIBUUQRW^=&33^100;.UW:#H5"F%5%L0/3IV]H"'0>=J\<D9M
M?;U29#<;@^J]4+26V'DG:MM""5)"2F70J/WSUCH8[POQEBV-7##[/:*5.,W1
MY;M53J&]MY:TI0HJ"I]4H2/LD):Q"E0\=.H-(MK:YPN)(H\LQ>?/CT)-PZDX
ME@[*J"R*[2+=*':IF:J``I]0$"]`].7K=_<3R[>[2JS5MV=%(XC:LH2E#BTR
MD0I:0%'<.OQC&U@]GWM^QR_HR.@L+2ZYMP.(2ZM;K2%@[DJ2TLE(*"`4SF!*
M,FRQHUK'FNYIW_(&-8^2M0BV^=)-7#F.-,@T["H%FDVATR2($13*G]_J*8`7
MZ!SYF*<X\FX79C8+!<G&[7KM0H!?CW3GXRJ91J2=.^L?;SSVP<*<D9(,LRJS
M-.WPE/D6A2F_-MD$^9*2`Y)("===HET`CZYC5NOS><\2Y-=.V:%'P=2WL%C7
M&3&/(UB(&ROU"MU+*G[0E3$S:'2(W13[>A>P#?4.<5'RC7T6#7;&6D+5?+Y6
MI=K*U2MSCK*1,,ZZZN$K4>\R(Y:_@RV7'E*PYJ\ZVC%,9MBV+=;$-A#3%2LR
M-2):>EH)0A,M"D'M%D['7XBVUZ>JM@9IR,#9H:4K\W'J]?:?1$RQ7CI)FKVB
M!O;=,W)R&Z#UZ&YBJ,]17G'>FNN&*+!B"T4'&<179S`V+9;"^*GS0[GW*GC6
M<?-I*4K#(#JF*9FZ>M$U!$X";J7Z\1,R8DZ>PQC6S96H6;9NKLGV3L95ZX56
MD6I45/G04#?5(-6UQ[8"G!,4I92N,Q/W`(A[(=.(B?;M%*<F>)#0S*]^LF0[
M'A<L;*7J1_+9&A:;:+/2Z;DJ2.N9=T]O=1K<I'PD^YD3&[71SI%,Y+^T$PB(
MC$HK#B@)")[RAI'J]F#'^(\5W/$E;/CS!-TI]_Q14(-`U<@Z=9:(;NK+N+8P
MIF:*:3#J(>V("4_41-U$1'DQ3N,Y]XM9Q$1^3%*<IB'*4Y#E$IR&`#%,4P=#
M%,4>H&*8!Z"`_7B$>&&ZO@KP%G:ZK;'ZGVZQZ(;EQHK2$-FW`Q@KD19)+JHN
M#3(U)CQ:Q%@C9!P(`Y$A">Z41%9-?^KR"`1+M'(AQ2?NC7LSX]S%J+935?RH
MZ_6K$;Y999*&WYTHI*5VQ!FA0IC@W)E/#!0C*Y7LA3_MF,5ZQ4AUQ<'`RS14
MO41RUQWS9R%QEN8QZL*[4I)'TS\W6`3T4A)(*"#J-B@D]TF,`<Q^V#AWG+;5
MY=;4HOR%I/UE-)BJ4`=4.+"2EU*A,$N)4L3T4(GG5O5G?W?-L9GK12;-XQ=-
M+"@,?9]G\E(%FM\]B*XJ8/>6@UW"#$^,:_.,5NI6D*6)8E3Z#\AR8.@V9E>9
MY3G-S5=\JK7JRL))&]7H;!_5;;$D(3\-HG\28R3Q_P`:X#Q58D8[@-LIK=;T
MI`5XT_M'2/UGW3-QU9E,E:B)_*D1LJ:'>+#3GQWUTS7!&-VSK(LLD8]VSE>#
M)VG,-ZD7'NF?R$W<'R1G;4'ZBQQ409@W1.`A[A3F#N&V8O12U*Z](]%^(IAQ
M"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(
M<0AQ"'$(<0B%\_=O\M9/O_D_V_D(;K_/3W?Y>?\`,4.GY#V/UOY#K^Z=/]?V
M]?3@](E/7O$PM?W9O^P_8)?NO[M^S+^[_P"P_P`C_-Z<1$<_$(<0AQ"'$(<0
MAQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"/
"_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g706848ex99_2logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g706848ex99_2logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`,P#R`P$1``(1`0,1`?_$`+D``0`"`@,!`0``````
M```````'"`8*`P4)!`(!`0`!!`,!`0`````````````!`@8'"`,$"04*$```
M!@(!`P,#``8$#P$````!`@,$!08'"``1$@DA$Q0Q(A5!(S,T%A=1,G>W<4)2
M8G)#8[,D-;8W.#EY"A$``0(%`P,"`P0%!PP#`````0(#`!$$!08A$@<Q01,B
M"%$R%&%Q@16Q0B,S=9%2<K,T%C>AT6*BLD-38R1TM#88.`G_V@`,`P$``A$#
M$0`_`-_CB$5:VQW4UBT?QK(96V=R[5<7U9F@LHR1EGR:MCL;A(AC!'56LMA5
MFK`_4,7M`K=$Y2"("H8A?NXB0DJ,A&LMG/RJ^1+>2)2L^IZ=2\:.FZLH0:EM
M3M*BHWRKFYVU7`\:WQUBT(^6F3U.4,9,7+MO'NVZ+?N.H\*4!*';H;?<+I4?
M26QAZHJMI5L:0IQ<AU.U`)D.YE(1U+G=+/8:/\POM534E$%!/D>=0TWN5H$[
MW%)3N/83F>PBQ.O?G9R?KA.U+#/F#Q0QQ&:U"T8XLW;PR)[]JKF=JHJ#1K-+
M62O"_8UET][!45*F<YDSB(*-6Q0'ITS,**5`A0,B#H01U!!U!'<&1$=_QI6@
M.LJ"FU`$$:@@]"DB84#V(F".AC9:I%ZI>2ZM"WC'EKKUWIUB9)2,%:*K+L9V
M"EF2Q0,FX8R<:NX:.""`]![3")3=0$`$!#DQQ2EUC*^(0XA#B$.(0XA#B$.(
M0XA#B$.(0XA#B$.(0XA#B$.(0XA#B$.(0XA#B$.(0XA#B$.(0XA&O9Y)O*EL
MY0MC9;0#07#%=L.Q++%[;*N1,[Y@G8^O8:P1C=_W%6O,L1Z`IRA8<`**@K=R
M'>H4G88PAP`I2@E()43(`"9).@``U)BL!M*"Z\H);$R23(`#4DDZ`#N3TCP"
M88XH3+(JV>\Q7F2\C&WKI8CPNR.>F#X==L52J)P5(A@#!<D?XEQ+$+#VLI.5
M1!@4I0]M/ITYM-Q7[5\QS=+5WRDJL^-+D1O$ZEU/7T-GY`?YR_OD(T.Y]]_?
M&O%JG\;P,-Y%FC<TD-J(HV%]/VKP_>D==C9EH028S"PS=AN5C=7*\V.9N]Q>
MI%0<66S.0>O$FA.X$HR(:`4L;7X-J4W:@R9I)((D`"E#IST0P/C3#.-K;^78
MI1H9)`\CRO6^Z?YSCBIDS^`T$>-7+7.7)O-MY-WS^Y.U#:5'Q4R#XZ9A,R0E
MIE,DB4Y;B-Q[ZQV-9ML[48.Q4V/0K5EQC=3%_F!A+)$$WN>&K^B'3O)-5"0*
MJG"R2H!T))Q@MWJ)ON*/7F/>4?;K@G)0<N"6Q;<G4)BJ82`%GMYF_E<'Q,MW
MP,9@X&]Y_+'"*F;2Z\;W@Z"`:*J626T]_IGC-;1'9,]A[@Q^-?*[E[6J\A:?
M$WF9[@:]V.1!U/>-S8JQN;9KGE]T4BBCEK@'*<LHJE!3#H!5(SBWWM/T3*%3
M14$>><O)7"F=\7U!5?:<O6<J(15LS4RH=MW4MJ/\U7?O'M-PG[GN)N>:-(Q>
MM%/D:4`NT%00BI;/?:#(/)'7<C61'IC:5\5OD76\C>$;E>+%A^:P;E'$.1IC
M#V7L>RL@C+-(?(%<(4)A*%DDBE,XC2JB(%!3JHF/VF,8?7F)8S^M.TR[1Z>\
M13#B$.(0XA#B$.(0XA#B$.(0XA#B$.(0XA#B$.(0XA#B$.(0XA#B$.(0XA#B
M$.(0XA&F?O40BOEY\D:2A"*)*>+2I%424*4Z:A0R#4A[5$S`)%""(>H"`@/+
MJP3_`-XLW\4I?ZY$6-RM,<6Y"02#^1U_30_V9SN(J$L8QC]QA$1[$@ZC_0"9
M0``_H``^@?HY[E+)*IGK'Y5FP$ID-!,_I,<7*8KAQ",NQR4JF4\-IJ%*HF.;
M,/J=BA2G("B>1:X9-4"F`2@JF/J4P?<7]`\P_P`^_P"#E_!Z?13_`-=$;'>T
M33W(XDH:*_,I?@6US'W'N.ACV$__`#OK)-Z[Y,W#A4B*"/D2S:LNNJ<")I))
MJE.JJJH<0*0A"%$3"(]``.O/&IO]VG[A'Z6*G]\K[XL15MK][?(#:;U*Z#AA
MS`^J="M]@Q_#[/9RK,QDB>SE::I(&B+2^Q1BV)DJ^W0HD%,MEF9)62?I`^62
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M"T-$YJ.:.P`6KR99-OD*PS5<INI%'0)%,7U#T]>(D(4K4"+.1N4\:S&/4<M1
M5^J$CBYQ!&LZ.0F=ABEZ:I72(F<'FRV--T:*&+(B43&6]WL``'J/$1(SEWBK
MV$O)+H?L?D);%&$-J,.9'R(0')VM3KUN8KRTNDS[_EKU]%4R(6!!L"8B<[,5
MP*`=1]/7B)*5`3(TB!?(EN[D#5:XX7@<?EKZZ-F/*S-V;S$4,DNK`QS^';)M
M6*I7C7\<Y=)N5^U40/ZE^GH/-JO;QPEC_*=GO-?D!J$KI@ANF+:]@#JTN$J4
M-JMX20F:=.O76-!?>-[H<MX$R+&[5B::-;==Y7JQ+S?D466W&4A*#N3L*@IR
M2I'4#X2,A[V[C2>OVO%.R+B]U".;?DR1A4Z8>89#*1IH=U%_FI*4.S3<MO?(
M@T50('W]`,N4?7EO<%<.TV?\A5F.Y0E]-HMC;GU`;5L7Y$K\:$;B#(E04>G1
M)B\_=-[D*KB/B&V9GA2Z9R^7MYGZ3RI\B"RIKS.N!.Y.Z22VD:R!6#$495V>
MS7.:R:H99Q[D7'E!L62;)66U\4L@,F#277=$23>1$,C('6231^8505TB'%?V
MC%`@]0'EUXKQCA5#R9E>)Y#;KC7VZVTSRJ4,[EJ;"9E+CA1(D[9;5$;=P.X1
M8.<\X\F7;A'`<^Q"[6FUWF]5;":[S[&TNJ4`%MM!S<`D*"BXA)\A24A)F#%V
M[3MGKUCM]/UW(67Z17K33&D>>VQ+N1%!RQ<O4VWMD0:*$^0X%PJX**:9`.IV
MF#J'UYA.U\3<@Y"Q3W''[16U%JK5K\#B432I*29S4-!(`S)D)B-G+WS_`,18
MA655DRW(;927^VMH-4TIS:I"E!.B4$;E3*@4I2"J1&D=6^W7U6CJ7&9`=9NH
MY*M,O5XV->DDP5<.7[4"&=-2QJ1#R15FQ%"F4`R0=A3`(^@ASLL<*\IU%Y=L
M#5DKC=&4!:T[)!*3\JMY.R1D0)*U(/PCIU/N6X*H\<8RM_)K8++4.*;;4')K
M4M,MR?$`704@@JFC0$$]1$R0&5L;VBA)Y1@KK79''JC!:3_BY*2;EA$F383%
M=+.'JAR)-OBG()5"G[3$,'00`>6=7XIDELOQQ>NHJAO(`X$?3E!\A4?E`2-3
MNZ@B8(U$9%M6>X9?,4&<6NYT;N(EI3AJPXD,I0GYBI9("=I!"@J1!$B)Q$]`
MW(UCRC:DJ31<RTR?M#E4Z+&(;R`HKR:J?7N3BS.DT$I$_0HB`(F.(A].O+LO
M_#G)N+VHWN^V:L8M:1-3A1,(![KVDE`_I`186*>XSA/-[ZG&<8R*W55\6K:V
MT%E*G5?!HK"0X?L03/M%-KSO6ZA-\J]@^,R)26^)%*Z[A[$J]CQ47C<G'9S#
M>/A'4P54ITE#S`,BBD4@]>_MZ]3>F8['P6U6\$5&;U-NK59:*A+C02N071;F
MRMQ+<I$!OR'<3VG+2-;<H]U#]K]U5+QA1WFV-X`:13+Y6W-2+D4/I0RIV<P?
M,&!M`/7;.9B7-&<P9-N&-<K6S.^4\<V]M5<AST>UL=9>QR,9`PT>U;N7#:7=
MMQ29MD4/>!1(%!]TB)@[Q$>6ESCA^,V?)+5:<$M=QHW:NWM+4R\E96ZXM12"
MVDS4HF4E$>DJ!VZ1D7VO\C9ED>&WZ_\`*%\M%?36^[/-IJ&%MAMAI"$J4'5I
MVH2D;@I`5ZP@C<9Q+]6W:U3NEL0I%:SA19.R.W/PV+(DH"*<@[%3VBMH]ZY(
MBR>+J']"E34,)OT=>6?=.%.5+-:57NY6.N:MJ$[E*V3*$RGN6D$J2`.I($N\
M9$L?N8X)R._)QJSY-;';NXO8A'DVAQ9,@EM:@$+43T"5$GM&4Y1VDU^PO/1U
M8R?E2J5"?E$DG#6*DWW1V5JNH*2+MTDB146314Y1`JBO80>@^OISY>,<79_F
M=`Y=,9M555V]HD*6A/IW`3*4DRW*`ZA,S'W,WYSXEXXNS-BS6^T-!=WDA26G
M%^L)49)6L)!V(,C)2Y#0ZZ1-\7*1LW',9B'?M)2*DVJ+Z.D6#A)TR?,W*956
M[IJY1,=)=!9,P&*8HB!@'J'+(JJ6IHJA='6-K:JFE%*T*!2I*@9%*@=00="#
MTC)M#745SHVKC;G6WZ!]M*VW&U!2%H4)I4E0F%)(U!!D1&"YFM<I0\/Y6O$&
M#8TW3,;7FUPY7J1EV9I2NUB4EX\':)3IF5;"[9D]PH&*)B]0ZAS@CN#4RCSG
MUZ\HF"F>G.L6:-R\Z8?Q!E'-&"VN79&`D)5&NA,-$7Q8V7?5&NN7#N3?M&[]
MP@B"*'OJBHH```]>(J*3N(2#*+D:U[CZR[?PL].:XYBI^4FU4?I1EK90+XQ)
MRKOW"8JMFUBK[Y)I-0QW:11.B+A`A52@(E$>@\124E/6(7RQY4/'S@_)$IB7
M*&U&+:O?:^\2C[5#+RZKU.FO5C@0C6YR<:V>1=57`Q@[B/ED#$_Q@#B)VJE/
MM%Z*[8X"WP,/::K-1EBK=@CFDO!ST*];R43+Q;Y$CAG(1S]HHJV=M'2!P,10
MAA*8H]0'B*8[GB$::.\__M\\D'_RUJ7]X%3Y=6"?^\6?^*4O]<B+&Y6_PLR'
M^!5__C.13]3^L'^@G_NR\]RE_-'Y5T=/Q/Z3''RF*H<0C+\;_P#=;#7]M.(O
M[Q*YS#_/O^#E_P#^Q/\`MHC8_P!HO_V0Q/\`B8_JUQZG^":N2%QPSY;ZC$NS
M1\K:=WMEJY&/RG%,S*0G(A[&,W95`]4S-G+HIP,'T[>O/&IO]VG[A'Z6*C1\
MG[8O+X4LMTUYIA2M57"D?2]C-04I["V<\/2HIQULJMIK]BF3,K8O`K*ED7M7
MOS!TA+M)(A!;N_EG`IQ,4W*XXW`=V[L8K!G#:/RE8+V7UUUY1SKI?F;(^>,R
MQ,2;"]!P_=6M^I>"&[]:3O.6+@]6R&_1K,%6*PW!NF[=MR)OI%P0B(&$!*")
M`003KTB&)#`-BSQB/S&.<>HG-FK!/DCL>R&#7:!2@Z0RAARL5.S1[1H82G5`
M+%%H/(TQ"B`J%=@41Z<DQ,Y%,^DHF#7O-R_E-VMA=K*&U0F\2:/ZO'-0XI1N
MJ>-7WNS'4W(W"/59O`,4TOAJ$9K1)C%#O;/'I3%-W=!Y'Z(A0V)EW/Z(L/X3
MZ=@VWZ1-+XXA*G;-@,D7');C=&:LT=&S&1'N?!N5@97BKY,/*INI9O\`@6Y4
MV;"/<B5!&**C[28)F]40[,*^SM%--N*7HW4,1X,Q!A"TQ3?Q_P!L\FL=7-TH
MNIVV6DL15"QNF4M*-\9J*KN5J]5<62^6F\>G+1L:/X0CI3VE`*)C%Y$5)*IS
M(]6W2+E^:"@:\570"QW!""J5*REC%>FO-.9^BQD1!WR!S8$]#M\=0F(G$*@W
MDB+S2YRMEF3`?:<,#*`H0R8#R8H1,JB'LKXZL&W.Y:6,+ZT3&S4G3IBO9FI0
M)\>'R=+50CM=T0B9C(MU6%OG$``I>@"5,`^G-[>,\F<XI]OE%EB"4/W#)&Y_
M%;*5I#B/M"FVW!]A,>4W-^"-<_>[FYX&ZE+E%:<.>2C6?CJ5-+4TY]A2\^P>
MT]H!BN&!8RY[F6;&^$+S'.3U[5K#N2V,BU5.J8K^;1-(Q5<(JF<IBHN$%3,4
M2$[0$?A#T'IS+V>55FX;MERS>QN)%PRF\4:D$2]+9V+>E\01Y5$_\P1KGQ70
MY'[D;W:.*\E86;+@N.7%"PJ9WNCRM4Z5`SVJ!+"`-#^P/;2.%Q8%I71K6ROO
M%#'?T#;R1J;DBA@.=%)!^B[9ICZB)>U!<2@`]/0O*F[>BDYPR2X,B5/7XBA]
M,NY*2E1_E$XFJNJJSVQX7:'E;JFT\@O4ROL3HX@?@%$?A%YZ%A['F7_*3LRC
MD:K0]OBJI3(R4CX>=9IR$:,D^;5R,!XNR7`[==5LV<G]KO*/8<0.7H8H#S!M
M^S#(<1]KN-.8Y5/4=555JT+<:44+V)+R]H4-0"0)R(F-#H3&TF+\;8;R)[Z<
MT1F5#37&AH;8AU#+Z`XWY%IIF@LH5-*BE*E;=P.U1"A(@&(YT8ULPG=,L;QL
M+30X6>C*);I>GTZ+EFB;YE78AZ]M(**1B;@#E;2":3!$B:Y0!1,I/M$.H\N3
MG+DG-;-BF#OVNO>IZFOI&ZBH6VHI4\XE+$@LB4T$J45).A)U$61[6N$>+\DS
MWDZFOUJIJNBM=>]24C3J0M%.TMVK!+05/:X$MH2E8]20G0B<5$7<6MKXX)F&
M@W+IO3R[3.8BVJ`HY%HS@DC#^.3D3(&]Q.'4?`)G!2]"G,`=0[NWF6D-VIWW
M',UE<E*KO_=<.,"0W*=/SE$]"X$Z(GJ!/M.,"MNW^D]G51;K4M:<>_OLINI)
M*]B&MDVDKV>H-%R94!H5!,_5*)<N^$+C=:SBB(;9(\?V/ET92">8ZLF.Y$U8
MNCEZ@B@NU;KR\:V.[]QR8H"J#P2_\0(AU`_+3LF;6>RW.ZUCMMS^X(4TZFK9
MJT>:G2DDA1#:U;9#]7QS]':47]DO&V09-9+';J:\\3VEX.LJH*BWO?3UJEA(
M*4K=;;*YDR*O.4_M.X5%@+1C&K)^4?#L!9JK67S][A0EJN9$8Y`T=-9$85>Q
M.W5H.D9(A5G_`.6CR+)KF*"@"0IO00Y8%LR>Z*]K]XK[955+=.B]%BGFL[VZ
M13S*4L`ST3XUE)2#+4CI&5;U@M@3[Y\?M5]M]"]6.8TBJK)-I+;UQ12U2EU4
MB!N7Y6TK2L@*FE)T($4A8/9]MH=D5%JK*M:5(;L':Y-=0_<5=*J&B8L3E=&)
MZ_!,J`B(&_5F5(F`^O;S-E0S0.\[VY;H:5>F\*W427.A?\B_EG^M+X:A)5+O
M&MM$[<VO:S>*=I3Z,8>Y(V7%36[<*?Z9H@';KM*AW])6$!7:/7$F._%R-(Q(
MH^+A))D=]75*A(MI=LA8Y&;."!VI;`YBG(3*HK.@`5RR(@AW^A^GIS4LY%[H
M?SN[)8_.U/!#HJ$*;464-B>[Q!8\8DGY2S-4ND;^M8C[&&\8Q\U)QEM@N4YI
M5I>2BI<>(3M%0II0>.Y7[P5$F]VBNT5&WGQO5J=GS(><:=9L&9359TR(1RU@
M3)KE@O-QD$FU;HMWM0[UF[I%\JQ:IG2*R62?-A-WAW%4`!RWP=D=TO.`V_"+
MQ37RU)76.&@NE$E0;6Z5$E-1($%(4HA1<2II<MNA22-??=+A^/8URI>.4+!6
M8O?UM6YH72QW);9>:9"$)"Z29"MY0A!2&5HJ&Y[AN"P#Z^8#R]CBSX8PC/1K
M>$QM'9`J[!.DT=V]8Q_M"Q:)D6@8%$XMRR!6!"_JP2+W&3$INWUYJ'GV(Y';
M,SO=#4J?N51;ZI1J:E*5+GN42'72)[-W?<9`S$X]"^).1,+OG&F+W6A12V2B
MN]`@45$I:&Y>-`"F&`=OD\8'I"1,ID9:QWVS/_C?L%_8CE?_`*#GN8ZC-`ZB
M-8W0/'M(O^QO@Y7NE7A;0:B^,/,%SJ19M@VDD(2TIVZ#B4)UFW=IJH$DFC)\
MH"*O;WHG$#D$#``A'>.11(2?Z7^>+S[V5NS8O\AM1OFM<82OYTS/XW=XZZK_
M``VQ1:.;M;\51]$G,++2*+0B82TY7K/9%2,%50.HD57VRCVCTY,0D^F1Z3$6
M0\3]5U*D/&[AP^-XW'L_4)_'!7N>WL^UAI.3E\HNXX5,S*9K5F4U72UP"Q?-
M"8++_K4^T0.`)@'$'-V_7\(L'IM*:18PU^@8[5*\U"*UW>9'M=>H:ZMUE5*:
MO<I&PN$Y:IXW?WF1[%X8)_W48YA$G-'%$#$9$[/3B*5;B?5UB\W$4QJ)^6;"
MNQNN6]^8=ZEM<;GL=IQGG5R'UPS*?!DD97-6(XN/DV<P[OD97E$C).AC)&/;
MG3,<#MEDQ.F<`-TYW+=7U-JN#%THB$UE,\AULD3`6A04DD=P"!IWCIW6TT&0
M6>JL-T256^LIW&'4@RW-NH*%@$:@E).HU$4#I@U7+=$>Y8UXR%%[%XMB@$UE
M>U2./%9DQ0!`Z*,LY844$;)5EV/3M7D622L:8WJ7IST?XM]W..Y%XK1R&A-L
MO2I)%0G^RN'035/5DD_'T_"/%;GS_P#.S,<.+^1<...7O&TA2S1KE]<RD3)"
M)"50``3Z?7\0(^%NNW=H)NF;A!VU5#JDY;*E60/_`$@!R"/:<HAT$INABC]0
M#FX-/44]6PBJI'$.TK@FE:"%)4#T(4)@QYNUE'66ZK<M]Q9=IZ]I12MIQ)0X
MA0,B%)4`00=(Y$RKN9"/AHYC)S4]+K$;0M;@8]S,V.:<J&`B;:)AF)%7CM4Y
MC``"!0('Z3!SXN395CN'6Q=XR>L9H[>@3W.*`*OL0GJI1[`#6+IP;C[-.2[X
MWCN"VZIN5V<5+:T@E*?])Q<MJ$CN5'2/MLV3L6ZO9#HS/**UCR_LDUL=>L>-
M]$=:A;W[-4O:8=^TF:V&<K/#B[A,40"<L@@HZCB'&243(9,XE]>>>/-?NE7F
M]LJ</PVE\.-U"=CK[X_;/)!!DA'1M)(ZGU1[)>V#V$-<77NBY'Y(KQ59I1K\
MC%-3*_Z:G64D3<<E-Y8!Z)]`,]8V%_!#JILUK?@G/UPVIH\+C#(NS^QMSV$2
MQM&2QI=]2(RY@59*"GE1*`-I1J;T,B(F.F'H<>[FG0```'01Z0.JWK*HO!LS
MXVM0]L+4RR'E'&ZT=E)BS2C$LKXXL,UC;)*T2B(BG$R%MJ3N.D9:.3Z_8FZ%
M8$P]"]H>G)BD*4GITC*-7=!]6=/%9V5PCC-I&7.U$(E;,F660D+ED^SMTCF4
M0:35ZL:[^><L$#&ZD;E5(@`^O9U]>(*4I76,G'#<!KW3]E[UKOC=O*Y4R]+W
M#,,K7E)($&^0,Q2%?(PCSOG3]3XL<VDG#!JDL(=$R)`8>G7B(G.4^D0]XR]2
MG&G&IE/QU8XN$C,JW*;M.9,Y?P\5#\0OF#*4PO9[BE'&;III'CXE=RFP0$O4
MHIM0,'];D#I$K5N5/M&-9L\3FEN=,D3^6)VCVFD76Z=ILB/\0Y`M6+6F2UB]
MA/EW^,J+]@PLL@=`@)'<K)_(42^TQS<F)"U`2BSD1J1K1!8"-JW&82QZVU]5
MA5:^YQ3_``\S4JCV-74%9Q\YFH0QWC]PY'WCNU#F=&7_`%GN=_0W$1N5NW3]
M45>PQXE-(\'9$KN3ZWCZQVFRT=8[C&Z.3K]:\CP&,'!NXI7./Z_:9%_%UQT@
MB;VT54TS*HDZ`0Q1`!XB2M1$HNE7,(8QJF2[CE^"J[-ED6^M$&%ILH&54>R;
M-L#($6Q_<.8B:10CD?0H!U]L.77<<WR:ZXU1XA752UX[0+*F&=`E"CNF=.I]
M:NOQ,8^L_&.$V'-+AR':Z%MO+[JV$5-1,E;B1XY)U,@/V3>@E\HCY\?8$Q)B
MNT7>Y4*EQ5<L>1'HO[=),DS%5E7!G;M^83@8QB))F>/E5!*0`*)C?X.<N09[
MEN4VRBLU^K7:BW6Y&RG0HZ-C:E/XG:E(F=9".#$.)N/L#OESR3$[8Q1WF\.>
M2K<0#-U16MP]=`"MQ:B!(3,1L;2K6HT.>`'&<4$.>]ADOX`*NBMRW4`*7\V0
M@*_8N8I``0#[1#TZ<N,<T\E"K%?^9N_6"A^CW23/Z?\`X9TZ=_C%G?\`QJX8
M^A-L%E8%!^9_F&P*5M%7MV^4:Z';Z9=):1*L!A7&E7R7;,OP=8:,<AWA@WC+
M/8DS*BZE&346ID4%BF.*8%(+)+Z``_8'+6K\UR6Z8U28A75*W,>H7"MEDRVH
M4=TR._ZROY8ONT\:X78\TK^0K91-M9=<V@W4U`)W.(3LD")R_P!VCH/U1'!0
M<&8NQC+WZ<I%4904IDZ5/-79TV,J)IN14.]4.X7`YS`43*2"P]"]`ZG'E=^S
MG*,GI*"AO=6M^EMC0;IDF7[-`"0`)?8A(U^$<.)\68+@]?=KIC%`W2UU[>+M
M8I),WEE3BB3,Z>IU9D.ZC'4U+6["=)HEDQG`X^@DJ);WKZ1LE:=M_G1LL[D>
MGRU7*+H5`$5.T.G3H)1`!#H(<[=VY(S6]WVFR6ON#YOM&A*&7DG:MM*/E"2F
M73_+WCH8_P`,\9XSBU;A5JM-,,6N#BUU%.L;VW5+`"BH*GV`E*4I"4HARA^/
M74G'%Q:WJMXGBOSL>[^=%?E5G$O'Q+PINY)Q'1SXZK5NH@/JF/:/8/J'KR\+
M][@^6<CLZK'<;L[]`XC:OQ@-K<3W"UIDH@]]=8QYBWM(X$P_(49/:+$R;FTY
MO;\JE.MMK!FE2&US2"D_*2#+M$[R&"L62N6(W-[^J,G&3HB%5KT?:#&5^6WB
M%FSUHHS*4#@D)#-Y!8OTZ]#CRQ:?.LII<4<PEBK6G&77@ZMG3:7`I*@KXSFA
M)_",HUG%F"U^>L\FU5`VO-J>F+"*F9W!HI6C;*<OE=6.G11CJJ=K9A*ATNVX
M[KF/H)O2;S)OIBUUQRW^=&33^100;.UW:#H5"F%5%L0/3IV]H"'0>=J\<D9M
M?;U29#<;@^J]4+26V'DG:MM""5)"2F70J/WSUCH8[POQEBV-7##[/:*5.,W1
MY;M53J&]MY:TI0HJ"I]4H2/LD):Q"E0\=.H-(MK:YPN)(H\LQ>?/CT)-PZDX
ME@[*J"R*[2+=*':IF:J``I]0$"]`].7K=_<3R[>[2JS5MV=%(XC:LH2E#BTR
MD0I:0%'<.OQC&U@]GWM^QR_HR.@L+2ZYMP.(2ZM;K2%@[DJ2TLE(*"`4SF!*
M,FRQHUK'FNYIW_(&-8^2M0BV^=)-7#F.-,@T["H%FDVATR2($13*G]_J*8`7
MZ!SYF*<X\FX79C8+!<G&[7KM0H!?CW3GXRJ91J2=.^L?;SSVP<*<D9(,LRJS
M-.WPE/D6A2F_-MD$^9*2`Y)("===HET`CZYC5NOS><\2Y-=.V:%'P=2WL%C7
M&3&/(UB(&ROU"MU+*G[0E3$S:'2(W13[>A>P#?4.<5'RC7T6#7;&6D+5?+Y6
MI=K*U2MSCK*1,,ZZZN$K4>\R(Y:_@RV7'E*PYJ\ZVC%,9MBV+=;$-A#3%2LR
M-2):>EH)0A,M"D'M%D['7XBVUZ>JM@9IR,#9H:4K\W'J]?:?1$RQ7CI)FKVB
M!O;=,W)R&Z#UZ&YBJ,]17G'>FNN&*+!B"T4'&<179S`V+9;"^*GS0[GW*GC6
M<?-I*4K#(#JF*9FZ>M$U!$X";J7Z\1,R8DZ>PQC6S96H6;9NKLGV3L95ZX56
MD6I45/G04#?5(-6UQ[8"G!,4I92N,Q/W`(A[(=.(B?;M%*<F>)#0S*]^LF0[
M'A<L;*7J1_+9&A:;:+/2Z;DJ2.N9=T]O=1K<I'PD^YD3&[71SI%,Y+^T$PB(
MC$HK#B@)")[RAI'J]F#'^(\5W/$E;/CS!-TI]_Q14(-`U<@Z=9:(;NK+N+8P
MIF:*:3#J(>V("4_41-U$1'DQ3N,Y]XM9Q$1^3%*<IB'*4Y#E$IR&`#%,4P=#
M%,4>H&*8!Z"`_7B$>&&ZO@KP%G:ZK;'ZGVZQZ(;EQHK2$-FW`Q@KD19)+JHN
M#3(U)CQ:Q%@C9!P(`Y$A">Z41%9-?^KR"`1+M'(AQ2?NC7LSX]S%J+935?RH
MZ_6K$;Y999*&WYTHI*5VQ!FA0IC@W)E/#!0C*Y7LA3_MF,5ZQ4AUQ<'`RS14
MO41RUQWS9R%QEN8QZL*[4I)'TS\W6`3T4A)(*"#J-B@D]TF,`<Q^V#AWG+;5
MY=;4HOR%I/UE-)BJ4`=4.+"2EU*A,$N)4L3T4(GG5O5G?W?-L9GK12;-XQ=-
M+"@,?9]G\E(%FM\]B*XJ8/>6@UW"#$^,:_.,5NI6D*6)8E3Z#\AR8.@V9E>9
MY3G-S5=\JK7JRL))&]7H;!_5;;$D(3\-HG\28R3Q_P`:X#Q58D8[@-LIK=;T
MI`5XT_M'2/UGW3-QU9E,E:B)_*D1LJ:'>+#3GQWUTS7!&-VSK(LLD8]VSE>#
M)VG,-ZD7'NF?R$W<'R1G;4'ZBQQ409@W1.`A[A3F#N&V8O12U*Z](]%^(IAQ
M"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(
M<0AQ"'$(<0B%\_=O\M9/O_D_V_D(;K_/3W?Y>?\`,4.GY#V/UOY#K^Z=/]?V
M]?3@](E/7O$PM?W9O^P_8)?NO[M^S+^[_P"P_P`C_-Z<1$<_$(<0AQ"'$(<0
MAQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"'$(<0AQ"/
"_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
